Cargando…

Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study)

Gut microbiota is believed to be a major determinant of health outcomes. We hypothesised that a novel oral microbiome formula (SIM01) can reduce the risk of adverse health outcomes in at-risk subjects during the coronavirus disease 2019 (COVID-19) pandemic. In this single-centre, double-blind, rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Martin C. S., Zhang, Lin, Ching, Jessica Y. L., Mak, Joyce W. Y., Huang, Junjie, Wang, Shilan, Mok, Chris K. P., Wong, Angie, Chiu, Oi-Lee, Fung, Yee-Ting, Cheong, Pui-Kuan, Tun, Hein-Min, Ng, Siew C., Chan, Francis K. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143994/
https://www.ncbi.nlm.nih.gov/pubmed/37111201
http://dx.doi.org/10.3390/nu15081982
_version_ 1785033996458000384
author Wong, Martin C. S.
Zhang, Lin
Ching, Jessica Y. L.
Mak, Joyce W. Y.
Huang, Junjie
Wang, Shilan
Mok, Chris K. P.
Wong, Angie
Chiu, Oi-Lee
Fung, Yee-Ting
Cheong, Pui-Kuan
Tun, Hein-Min
Ng, Siew C.
Chan, Francis K. L.
author_facet Wong, Martin C. S.
Zhang, Lin
Ching, Jessica Y. L.
Mak, Joyce W. Y.
Huang, Junjie
Wang, Shilan
Mok, Chris K. P.
Wong, Angie
Chiu, Oi-Lee
Fung, Yee-Ting
Cheong, Pui-Kuan
Tun, Hein-Min
Ng, Siew C.
Chan, Francis K. L.
author_sort Wong, Martin C. S.
collection PubMed
description Gut microbiota is believed to be a major determinant of health outcomes. We hypothesised that a novel oral microbiome formula (SIM01) can reduce the risk of adverse health outcomes in at-risk subjects during the coronavirus disease 2019 (COVID-19) pandemic. In this single-centre, double-blind, randomised, placebo-controlled trial, we recruited subjects aged ≥65 years or with type two diabetes mellitus. Eligible subjects were randomised in a 1:1 ratio to receive three months of SIM01 or placebo (vitamin C) within one week of the first COVID-19 vaccine dose. Both the researchers and participants were blinded to the groups allocated. The rate of adverse health outcomes was significantly lower in the SIM01 group than the placebo at one month (6 [2.9%] vs. 25 [12.6], p < 0.001) and three months (0 vs. 5 [3.1%], p = 0.025). At three months, more subjects who received SIM01 than the placebo reported better sleep quality (53 [41.4%] vs. 22 [19.3%], p < 0.001), improved skin condition (18 [14.1%] vs. 8 [7.0%], p = 0.043), and better mood (27 [21.2%] vs. 13 [11.4%], p = 0.043). Subjects who received SIM01 showed a significant increase in beneficial Bifidobacteria and butyrate-producing bacteria in faecal samples and strengthened the microbial ecology network. SIM01 reduced adverse health outcomes and restored gut dysbiosis in elderly and diabetes patients during the COVID-19 pandemic.
format Online
Article
Text
id pubmed-10143994
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101439942023-04-29 Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study) Wong, Martin C. S. Zhang, Lin Ching, Jessica Y. L. Mak, Joyce W. Y. Huang, Junjie Wang, Shilan Mok, Chris K. P. Wong, Angie Chiu, Oi-Lee Fung, Yee-Ting Cheong, Pui-Kuan Tun, Hein-Min Ng, Siew C. Chan, Francis K. L. Nutrients Article Gut microbiota is believed to be a major determinant of health outcomes. We hypothesised that a novel oral microbiome formula (SIM01) can reduce the risk of adverse health outcomes in at-risk subjects during the coronavirus disease 2019 (COVID-19) pandemic. In this single-centre, double-blind, randomised, placebo-controlled trial, we recruited subjects aged ≥65 years or with type two diabetes mellitus. Eligible subjects were randomised in a 1:1 ratio to receive three months of SIM01 or placebo (vitamin C) within one week of the first COVID-19 vaccine dose. Both the researchers and participants were blinded to the groups allocated. The rate of adverse health outcomes was significantly lower in the SIM01 group than the placebo at one month (6 [2.9%] vs. 25 [12.6], p < 0.001) and three months (0 vs. 5 [3.1%], p = 0.025). At three months, more subjects who received SIM01 than the placebo reported better sleep quality (53 [41.4%] vs. 22 [19.3%], p < 0.001), improved skin condition (18 [14.1%] vs. 8 [7.0%], p = 0.043), and better mood (27 [21.2%] vs. 13 [11.4%], p = 0.043). Subjects who received SIM01 showed a significant increase in beneficial Bifidobacteria and butyrate-producing bacteria in faecal samples and strengthened the microbial ecology network. SIM01 reduced adverse health outcomes and restored gut dysbiosis in elderly and diabetes patients during the COVID-19 pandemic. MDPI 2023-04-20 /pmc/articles/PMC10143994/ /pubmed/37111201 http://dx.doi.org/10.3390/nu15081982 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wong, Martin C. S.
Zhang, Lin
Ching, Jessica Y. L.
Mak, Joyce W. Y.
Huang, Junjie
Wang, Shilan
Mok, Chris K. P.
Wong, Angie
Chiu, Oi-Lee
Fung, Yee-Ting
Cheong, Pui-Kuan
Tun, Hein-Min
Ng, Siew C.
Chan, Francis K. L.
Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study)
title Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study)
title_full Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study)
title_fullStr Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study)
title_full_unstemmed Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study)
title_short Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study)
title_sort effects of gut microbiome modulation on reducing adverse health outcomes among elderly and diabetes patients during the covid-19 pandemic: a randomised, double-blind, placebo-controlled trial (impact study)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143994/
https://www.ncbi.nlm.nih.gov/pubmed/37111201
http://dx.doi.org/10.3390/nu15081982
work_keys_str_mv AT wongmartincs effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT zhanglin effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT chingjessicayl effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT makjoycewy effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT huangjunjie effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT wangshilan effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT mokchriskp effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT wongangie effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT chiuoilee effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT fungyeeting effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT cheongpuikuan effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT tunheinmin effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT ngsiewc effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy
AT chanfranciskl effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy